Pharmacosmos Continues Its Growth – Revenue Surpasses DKK 3 Billion

Holbaek, 1 July 2025

Pharmacosmos Continues Its Growth – Revenue Surpasses DKK 3 Billion

Pharmacosmos is continuing its growth journey, reporting a total revenue increase of 40% for the 2024/25 financial year, an even higher growth rate than in the previous fiscal year. Operating profit also increased significantly, rising by 21% over the past year.

Highlights for the Period 1 May 2024 to 30 April 2025

• Revenue for the period increased by 40% to DKK 3,362 million (2023/24: DKK 2,403 million).

• Acquisition in September 2024 and subsequent successful integration of G1 Therapeutics Inc. and its product Cosela®.

• Growth was driven across all regions, including continued strong growth for Monofer®/Monoferric® in the US.

• Operating profit for the year totalled DKK 833 million (2023/24: DKK 689 million).

• Other operating income of DKK 1,494 million relates primarily to legal settlements (2023/24: DKK 301 million).

• Net profit was DKK 1,652 million (2023/24: DKK 809 million).

• For 2025/26, revenue is expected to continue to increase and the group's result is expected to be positive.

Key Financial Figures

(DKK million)

2024/25

• Revenue: 3,362

• Operating profit: 833

• Profit before income taxes: 2,129

• Net profit: 1,652

• Net cash flow from operating activities: 2,142

• Equity: 2,273

• Average number of FTEs: 652

2023/24

• Revenue: 2,403

• Operating profit: 689

• Profit before income taxes: 1,056

• Net profit: 809

• Net cash flow from operating activities: 542

• Equity: 1,832

• Average number of FTEs: 573

 (Source: Pharmacosmos Holding A/S, Annual Report 2024/25)

Tobias S. Christensen, President & CEO, said in connection with the publication of the financial statements:

This year marks a new milestone for Pharmacosmos. It took us 57 years to reach a revenue of DKK 1 billion, 2 years to reach DKK 2 billion – and just 1 year to reach DKK 3 billion. In addition to the significant growth, another milestone during the financial year was the acquisition of G1 Therapeutics and the exceptionally successful integration of its product Cosela® into our portfolio and organisation. This has provided us with valuable experience and leaves us well equipped for continued organic growth and future acquisitions.'' 

About Pharmacosmos

Pharmacosmos A/S is a global leader in carbohydrate chemistry and innovative treatments for iron deficiency and iron deficiency anaemia. Building on our foundational expertise in carbohydrate chemistry and cell cycle biology, we develop innovative treatments for unmet patient needs, with a focus on iron metabolism and blood-related disorders. Founded in 1965 and headquartered in Denmark, our team is made up of more than 700 specialists across the UK, Ireland, the Nordics, Germany, the USA, and China

For more information, please contact:

Christian Lundquist Madsen,

Vice President Global Marketing & Communication

+45 5948 5959 clm@pharmacosmos.com